A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)

J Infect Dis. 1999 Sep;180(3):843-6. doi: 10.1086/314951.

Abstract

To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / blood
  • Antibody Formation
  • Avipoxvirus / genetics
  • Avipoxvirus / immunology*
  • Cytomegalovirus / genetics
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Infections / immunology*
  • Cytomegalovirus Infections / prevention & control
  • Double-Blind Method
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Genetic Vectors
  • Humans
  • Male
  • Middle Aged
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology*
  • Viral Envelope Proteins / immunology*
  • Viral Vaccines / adverse effects
  • Viral Vaccines / immunology*

Substances

  • ALVAC vaccine
  • Antibodies, Viral
  • Vaccines, Attenuated
  • Viral Envelope Proteins
  • Viral Vaccines
  • glycoprotein B, Simplexvirus